demonstrated that LRRK2‐IN‐1 (a nonspecific selective inhibitor of DCLK1) enhanced the cytotoxic effects of gemcitabine via suppressing Chk1 phosphorylation in pancreatic cancer cells. The gene discussed is DCLK1; the disease is familial pancreatic carcinoma.